跳至主要内容
临床试验/NCT04610814
NCT04610814招募中不适用

Blood Transfusion by Boston MedFlight Registry

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2019年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
1
主要终点
30-day mortality

研究概览

简要总结

The primary aim of this observational registry is to study the outcomes of patients with hemorrhagic shock transported by Boston MedFlight receiving blood products during transport.

详细描述

Boston MedFlight, a critical care transport organization, based on a consortium of the academic medical centers in Boston, will begin carrying PRBC in 2019. The program is intended to provide BMF clinicians with 24-hour immediate access to appropriate blood products to be utilized if needed for patients following life-threatening illness or injury. The four fundamental goals of this program are: save lives' ensure transfusion safety; minimize blood product waste; and conduct continuous quality assurance. Our goal is to observationally evaluate this new protocol of administering blood products in the pre-hospital setting. We will collect data on patients with hemorrhagic shock being transported by Boston MedFlight, who receive or would have been eligible to receive pre-hospital blood transfusion by the inclusion criteria.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Age < 18 years old

结局指标

主要结局

30-day mortality

时间窗: 30 days

30-day all cause mortality

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Susan Renee Wilcox

Chief, Division of Critical Care, Department of Emergency Medicine

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验

Blood Transfusion by Boston MedFlight Registry | 临床试验